09-002 Stemcells Execsumm
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View 09-002 Stemcells Execsumm as PDF for free.
More details
- Words: 3,797
- Pages: 6
EXECUTIVE SUMMARY April 2009
Print: $3,200 $2,700 Electronic (.pdf): $5,200 $4,500 Enterprise: $7,940 $6,750
Capitalizing on New Opportunities for Stem Cell Products
Overview
REPORT #09-002
Report Objectives • Identify new/expanding stem cell research opportunities as a result of the ban on federal funding for research on human embryonic stem cells being lifted • Estimate market share for stem cell research products • Project growth of stem cell research products by market segment and geographic region • Learn types and species of stem cells scientists intend to use • Determine level of satisfaction with stem cell media and unmet needs with respect to stem cell products and cell lines • Uncover interest in integrated stem cell workflow products and services
This analysis also provides suppliers with critical insight into optimizing product offerings based upon scientists’ level of satisfaction with stem cell culture products and the level of interest in developing integrated stem cell product lines and services. The scientists surveyed share their opinions on what new product/technologies would be most beneficial to their research. Additionally, the report reveals what channels stem cell scientists use to access information relevant to their research, which in turn can be used by suppliers to more effectively target their products and services. The March 2009 policy change could have major implications for life science suppliers as academic scientists consider conducting research on previously unavailable embryonic stem cell lines. While the excitement about embryonic stem cell research is on the rise, including in the pharmaceutical and biotech industry, suppliers need actionable information about scientists’ plans to pursue research using all types of cell lines in a global market. This report provides insights into the origins and sources of stem cells currently used in the lab (adult, embryonic, induced and pluripotent) and those likely to be used over the next several years—in addition to differentiated cell types and associated diseases under investigation—allowing suppliers to anticipate the types of stem cell culture products scientists will need to purchase. Moreover, this report includes a supplemental section about scientists who plan to conduct stem cell research in the near future to help companies better anticipate the stem cell product needs of new customers. Capitalizing on New Opportunities for Stem Cell Products provides a roadmap for stem cell product suppliers to help navigate a landscape that is poised for change—and growth. This analysis was designed to guide suppliers in redirecting resources to new areas and markets, and to help refine current offerings by making them more responsive to scientists who are already engaged in stem cell research.
hoose C y h W eport? This R age 4) (see p
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
BioInformatics market insights from gene to drug 2111 Wilson Blvd Suite 250 Arlington, VA 22201 www.gene2drug.com 703.778.3081 (fax) Executive Summary Page 1 of 6
Analyst Expertise
In Capitalizing on New Opportunities for Stem Cell Products, we surveyed close to 500 scientists from around the world about their current—and planned—areas of research, usage of stem cell products and preferred suppliers. This report will help you to determine areas poised for growth (i.e., media, sera, supplements and cell lines) in the stem cell research products market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure your leading position in this
expanding market. For tactical planning purposes, the report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers. Combined with data on scientists’ stem cell research budgets and expected changes in spending through 2011, suppliers can use this information to anticipate areas of growth and product saturation.
Company Information
As a result of the March 9, 2009 reversal of the 2001 restrictions on federal funding of human embryonic stem cell research, suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell products market. Additionally, given that practical stem cellbased therapies can take years to develop, suppliers would benefit from a clear understanding of the wide range of products that support basic stem cell research already in progress. Capitalizing on New Opportunities for Stem Cell Products, BioInformatics LLC’s latest report, will enable suppliers to respond quickly to a market disrupted by an Executive Order, and to gain a better understanding of how today’s stem cell products market is driven by long-term stem cell research requirements.
Order Form
Overview
Report Highlights
This pre-publication discount price is only available until May 17, 2009!
Capitalizing on New Opportunities for Stem Cell Products REPORT #09-002
• Projected growth of stem cell research products market by market segment and geographic region • Anticipated stem cell research budgets for 2009 by market segment and geographic region • Expected change in spending on stem cell products and cell lines over the next two to three years (through 2011)
• Differentiated cell types that were/are/will be the focus of stem cell research for 2008, 2009, and two to three years from now (2010 and 2011) • Diseases that are the focus of stem cell research by type of stem cell • Top scientific journals respondents rate as most critical to their stem cell research • Critical stem cell conferences Stem Cell Culture Products: Top Suppliers and Budgets
• Suppliers from whom respondents purchase stem cell culture products
Frequently Asked Questions (related to):
• Products needed to support scientists’ current stem cell research
• Percent of stem cell culture product purchases made from leading suppliers
• Cell types and disease that are/will be the focus of stem cell research
• Estimated 2008 budget for stem cell culture products
• Use of embryonic versus induced pluripotent cells for specific applications • Unmet product needs and product differentiation strategies • New product and/or service development opportunities • Best channels by which to communicate with and market to stem cell researchers
Section 2. Methodology & Demographics
• Percent of 2008 budget spent on stem cell media, sera, and supplements • Estimated 2009 budget that will be dedicated to stem cell culture products and stem cell lines • Percent of 2009 budget that will be spent on stem cell media, sera, and supplements • Expected change in expenditures on stem cell media, sera, and supplements over the next two to three years (2010 and 2011) Stem Cell Media: Usage, Product Features and Special Requirements
• Objectives
• Types of media used to grow and culture stem cells
• Questionnaire design
• Percent of media that is custom vs. off-the-shelf
• Survey population
• Estimate of stem cell culture media used per month in 2008
Section 3. Presentation of the Survey Data: Respondents Conducting Stem Cell Research Research Overview and Applications
• Estimate of stem cell culture media expected to be used per month in 2009 • Expected change in stem cell culture media usage for two to three years from now (2010 and 2011) • Importance of xeno-free and animal-free types of stem cell culture media
• Length of time conducting research • Goals of stem cell research
Report Highlights
• Estimated market share of top suppliers by stem cell research product category (i.e., media, sera, supplements, and cells)
• Impact on research of lifting US restrictions on federal funding of embryonic stem cells
Analyst Expertise
• Estimated market share for stem cell research products by market segment and geographic region
• Features of stem cells studied
• Advantages of stem cell culture media from primary supplier
• Source, type, and number of different stem cell lines used in 2008
• Satisfaction with features of stem cell culture media from primary supplier
• Source, type, and number of different stem cell lines expected to be used in 2009
• Requirements for GMP conditions for stem cell culture products
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Executive Summary Page 2 of 6
Company Information
Market Size and Share and Market Growth Potential
• Source and type of stem cell lines plan to use two to three years from now (2010 and 2011)
Order Form
Section 1. Analysis
Overview
Report Highlights
Capitalizing on New Opportunities for Stem Cell Products REPORT #09-002 Additional Analysis by:
• General sources from which respondents acquire stem cells
• Market segment
• Percent of stem cell purchases made from major sources in 2008
• Years of experience
• Percent of stem cell purchases expected to be made from major sources in 2009
• Research focus
• Geographic region
age (see p
4
• Lab size
• Commercial suppliers and/or national bank/repositories from which respondents currently purchase stem cells
Section 4. Appendices
• Percent of stem cell purchases made from commercial suppliers and/or national bank/repositories
Appendix A. Respondents Planning to Conduct Stem Cell Research
• Estimated 2008 budget for stem cell lines • Estimated 2009 budget that will be dedicated to stem cell lines • Reasons why respondents acquire stem cells from their primary suppliers • Percent of stem cells grown on feeders and sources of feeder cells • Use of 3-D cell culture in stem cell research • Reasons for interest in 3-D cell culture for stem cell research Supporting Products, Technologies, and Services
• Techniques respondents use to identify differentiated cell types derived from stem cells • Major disadvantages of techniques used to identify differentiated cell types derived from stem cells • Primary supplier of consumable products used to perform techniques for identifying differentiated cell types derived from stem cells • Stem cell-specific kits or panels currently used and planned to use in the next 12 months • Stages of stem cell workflow processes with which respondents are involved
• Time frame that respondents plan to begin stem cell research • Sources of funding that will support future stem cell research • Anticipated annual budget for stem cell culture products and stem cell lines • Sources and types of stem cells respondents plan to use in their research
Analyst Expertise
Report Highlights
• Stem cell type
• Differentiated cell types that will be the focus of stem cell research • Diseases that will be the focus of stem cell research by cell type • Sources from which respondents plan to acquire stem cells Appendix B. Verbatim Responses to Questions
Company Information
• Expected changes in the percent of stem cell purchases expected to be made from commercial suppliers over the next two to three years (2010 and 2011)
hoose Why C port? e This R )
• Do you think your stem cell research will change due to the lifting of US restrictions on federal funding for human embryonic stem cell research by the new presidential administration? Why or why not? • Like many stem cell pioneers, Ian Wilmut, the creator of Dolly the sheep, has embraced an alternative approach. Are induced pluripotent stem cells the beginning of the end for embryonic cloning? Why or why not?
• Stage of stem cell workflow that respondents would most like a new product/technology to facilitate their research • Types of stem cell-related services that respondents would be most interested in obtaining from suppliers .
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Executive Summary Page 3 of 6
Order Form
Stem Cells: Sources, Budgets, and Special Requirements
Overview
Report Highlights (continued)
#09-001
Prospering in a Down Market: Strategies for Life Science Suppliers
March 2009
159 Pages
#08-047
The Brave New World of Scientific Publishing
November 2008
154 Pages
#08-019
Enabling Discovery: The 2008 Life Science Industry Awards
June 2008
101 Pages
#08-008
Instrumentation Service Contracts: Opportunities for Differentiation
July 2008
136 Pages
#08-007
Protein Research: Strategies for Marketing to Chemists and Biologists
September 2008
123 Pages
#08-006
Understanding Switching Dynamics: Maximizing Customer Retention in the Life Science
March 2008
173 Pages
#08-004
Life Science Product Catalogs: Techniques to Increase Sales
March 2008
92 Pages
#08-003
Conference & Exhibit Strategies in the Life Sciences: What’s Working Now
February 2008
135 Pages
#08-002
Advertising to Life Scientists: Resolving the Print vs. Online Dilemma
February 2008
105 Pages
#08-001
Marketing to Life Scientists: Capturing Customers’ Attention in Applied Markets
January 2008
156 Pages
TM
Report Highlights
Life Science Marketing
Overview
Other Recent Publications*
Sources of Independent, Unbiased Research Unlike reports from other firms that are based on an analyst’s subjective summary of information from publicly available sources, our reports are based on the results of detailed surveys of hundreds—even thousands—of scientific and medical professionals who buy your products.
Carefully Selected Survey Participants When others promote results from their online surveys, they fail to mention the uncontrolled nature of their broadcast email invitations. To provide you with the most valid and accurate results possible, the respondents to our surveys are members of our unique online panel—The Science Advisory Board—which consists of more than 43,000 verified life science and biomedical professionals who have agreed to take part in our surveys, focus groups and other market research activities. These respondents are carefully selected based on their professional qualifications, market segments and geographic regions—we can even select them based on the products they use and their preferred suppliers.
Don’t settle for an imitation. Invest in the most direct source of information from the scientists who buy your products, and the expert team that has been monitoring your clients since 1994.
Developed by a Team of Experts Complimentary Consulting Provided
Our questionnaires are developed by a multidisciplinary team of scientists, industry veterans and market research experts with years of experience. These professionals understand that survey questions need to be asked in a way that ensures the answers will directly address the business challenges you face. Once the survey data is collected, this same team creates a unique report that presents the reader with a thorough understanding of the topic and the scientific and business implications of the results based on sophisticated statistical analytics.
With your purchase, we offer one free hour of consultation with our talented team of scientific and business analysts who created the report. During this consultation, we can answer any questions you may have about the survey results and what we believe to be the significant trends affecting the market.
Custom Analysis & Research Available If you’d like to delve deeper into the data from a study, we can always perform custom cross-tabulations or other analysis on your behalf. We can even pose follow-up questions to respondents who answered in a particular way or conduct a custom study to extend your knowledge.
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Executive Summary Page 4 of 6
Company Information
The design and analysis of Capitalizing on New Opportunities for Stem Cell Products was spearheaded by BioInformatics LLC’s Vice President of Advisory Services Tamara Zemlo, Ph.D., MPH, who has been the lead analyst on over 80 syndicated market research reports. For this study, Dr. Zemlo consulted with multiple stem cell products vendors to optimize the relevance of this study with regards to the current stem cell research market.
Order Form
With hundreds of stem cell products market reports to choose from, why choose ours?
Analyst Expertise
* See Web site www.gene2drug.com for a complete listing.
Our Valued Clients Biotechnology/Life Science 454 AbCam Accelrys Affymetrix Agencourt Bioscience Agilent Technologies American Type Culture Collection Anachem Antibodies By Design Apple Computer Applied Biosystems Applied Precision Axxora BD Biosciences Beckman Coulter Biacore Bio-Rad Laboratories Bioneer Biotage BioTrove Blue Heron Biotechnology Caliper Technologies Callida Genomics Cambrex Bio Science Carl Zeiss Cell Signaling Technology Celliance Charles River Laboratories ChromaVision Medical Systems Cipher Systems Clontech Laboratories Corning DAKO DNAStar Dow Corning Dynal Biotech eBIOINFORMATICS Edge Biosystems Eksigent Technologies EM Separations Technology EMD Biosciences Entelechon Epigenomics Epitomics Epoch Biosciences
Eppendorf Eurogentec Expression Pathology Fermentas Fluidigm GE Healthcare Gen-Probe Gene Codes Gene Logic Gene Therapy Systems Gentra Systems GenVault Corporation Genzyme Guava Technologies Helicos BioSciences Hewlett-Packard High Throughput Genomics Hitachi Instruments Hybrigenics Hyseq IBM Life Sciences Illumina Immunotech InforMax Integrated DNA Technologies Invitrogen JRH Biosciences Kirkegaard & Perry Laboratories Kodak Scientific Imaging Leica Microsystems LI-COR LION bioscience Lonza Luminex MDS Sciex Mettler-Toledo AutoChem Millipore MiraiBio Molecular Devices MWG Biotech New England Biolabs NuGEN Technologies Ovid Technologies Pall Life Sciences Percival Scientific PerkinElmer Life Sciences Photometrics
Plexagen Diagnostics Post Genome Institute Promega Protein Forest Proteome Systems Qbiogene QIAGEN R & D Systems Ribomed Biotechnologies Rosetta Biosoftware Sachem Sarstedt Sandia National Laboratories SAS Institute Schott Nexterion Sequenom Serologicals Serotec Sigma-Aldrich Solexa SomaLogic Source Precision Medicine Stratagene Stressgen Biotechnologies Takara Mirus Bio Tecan The Jackson Laboratory Thermo Fisher Scientific Thomas Scientific Tocris Cookson Transgenomic UVP Varian VWR International Vysis Waters Whatman Medical Diagnostics Applied Imaging Ciba Corning Diagnostics Dade Behring Diagnostic Products Diametrics Medical Hewlett-Packard Medical Products LifeScan Mallinckrodt
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Ortho-Clinical Diagnostics Radiometer America Tektronix Pharmaceuticals Abbott Laboratories Amgen AstraZeneca Aventis Baxter Healthcare Bayer Boehringer Ingelheim Pharmaceuticals Cardinal Health Centocor Hoechst Marion Roussel ICN Pharmaceuticals Janssen Pharmaceutica Merck Novartis Pharmaceuticals Novo Nordisk Pharmaceuticals Pfizer Schering-Plough Professional Services & Finance Adjuvant Partners Adventus Research Agency.com Anvil Group Atlas Venture Battelle Memorial Institute BioOnline Citadel Investment Group Doran Media Services Fidelity Management and Research Foley & Lardner Gerson Lehrman Group HSBC Securities Infotrieve Innovative Marketing Group McKinsey & Co. Nathan Associates National Research Council of Canada Novintel
Phillip Johnson & Associates PA Consulting Perry Ballard Piper Jaffray Ruder Finn Scherago International Select Equity Group Stephan & Brady The Strategy Works UBS Warburg Publishers & Associations Academic Press American Academy of Pediatrics AAAS/Science American Medical Association American Society for Cell Biology American Society for Microbiology American Society of Human Genetics BioTechniques/Eaton Publishing Blackwell Publishing Cold Spring Harbor Laboratory Press Elsevier Federation of Amer. Societies for Experimental Biology Harvard University Medical School John Wiley & Sons Mary Ann Liebert Publishers Nature Publishing Group New England Journal of Medicine Society for Neuroscience Springer-Verlag Stanford University High Wire Press Thomson ISI Wolters Kluwer
Executive Summary Page 5 of 6
Overview Report Highlights
BioInformatics offers both published reports and custom research services. Published reports allow marketing professionals to share in the results of broad-based market studies that provide access to high quality research at an affordable price. Our custom research is tailored to the specific needs of the company’s executive management. For more information about BioInformatics’ product and service offerings, please visit our Web site at www.gene2drug.com, call 703.778.3080 or email [email protected].
Analyst Expertise
Our multi-disciplinary team of scientific experts and business analysts creates value for our clients by combining extensive industry knowledge and experience. We offer a variety of products and services that enable executives to see themselves, their market and their competitors through the eyes of the most important information source of all—customers. We can precisely meet the needs of our clients through the most appropriate mix of research methodologies, including: • Online Surveys • Online Focus Groups • Mail Surveys • Telephone Interviews
Company Information
Since our inception in 1994, BioInformatics has provided critical market intelligence to leading companies serving the life science, medical device and pharmaceutical industries. We support clients across the entire market spectrum—from scientific research to diagnostics and therapeutics—providing high-level management with market insights from gene to drug.
Our strength lies in our ability to integrate our understanding of science and medicine with cutting-edge market research techniques. As one of the first firms to recognize how the World Wide Web has transformed market research, BioInformatics formed The Science Advisory Board. Launched in 1997, this global community currently consists of more than 43,000 life science researchers, physicians and biomedical professionals who convene regularly via the Web to voice their opinions on a wide variety of issues relating to biomedical research and clinical technologies. Clients tap into this panel of experts and receive answers to their critical marketing questions in days, rather than weeks. In addition to providing real-time insights into the perceptions of the market, posing questions to The Science Advisory Board offers substantial cost savings over gathering information via traditional market research techniques.
Order Form
About BioInformatics, LLC
BioInformatics market insights from gene to drug
REPORT #09-002
Overview
Capitalizing on New Opportunities for Stem Cell Products PRE-PUBLICATION DISCOUNT PRICES are only available until May 17, 2009! Print Copy—$3,200 Now $2,700! Electronic Copy (includes one print copy)—$5,200 Now $4,500! Enterprise Copy (includes one print copy)—$7,940 Now $6,750!
Ordering Information
Payment must be made within 30 days and in U.S. dollars. BioInformatics’ Federal Tax ID #: 54-2001907.
This format allows an unlimited number of users within your company to access the report regardless of geographic location. You may place the electronic copy (PDF) on your secure, corporate intranet or share it with co-workers via email. In addition to providing greater accessibility, the electronic copy allows you to easily navigate the document with the help of bookmarks, quickly search key words or phrases and print out any page. One print copy of the report is also provided at no additional cost.
Credit Card
Data Set
You may charge your order to American Express, MasterCard, Visa, Diner’s Card or Discover. Please include your credit card account number, expiration date and signature.
To accommodate your unique needs, the raw data is also available. With the data, you can analyze respondents’ answer choices in any way needed, including cross-tabulations, correlations, etc. The data set is offered in two formats: SPSS® Base or Microsoft® Excel, and may only be purchased in conjunction with the company-wide electronic copy of the report.
Analyst Expertise
Wire transfers should be sent to: SunTrust Bank, 2121 15th Street, Arlington, VA 22201, SWIFT #SNTRUS3A, ABA #071000104, Account #702260169.
I wish to order the following format of REPORT #09-002, Capitalizing on New Opportunities for Stem Cell Products
Discount Price
$2,700
$________
$4,500
$________
$6,750
$________
Excel or SPSS (circle one)
+$1,200
+$________
o Print Copy o Electronic Copy (.pdf, includes print copy)
o Enterprise Copy (.pdf, includes print copy) o Add Data Set
Additional print copies
_____ x $300 each
+$________
Promo Code ___________ –$________ Shipping & Handling (Add $15 for U.S., $50 for Int’l) +$________ Total $________
Company Information
Wire Transfers
Report Highlights
Electronic Copy
To place an order, fill out this form and mail it to BioInformatics, LLC or fax it to 703.778.3081. Alternatively, you may submit your order by emailing [email protected], calling 703.778.3080 or visiting www.gene2drug.com/order/201/.
o Check Enclosed (Payable to BioInformatics, LLC)
o Bill Me Title
o Am Ex o MasterCard o Visa o Diner’s Card o Discover
Organization
/
Street Address
Credit Card #
City, State/Province, Postal Code
Exp Date (MM/YY)
Name on card______________________________________________
Country
Order Authorized By: Phone
Fax
__________________________________________________________ Signature
Email
Date
BioInformatics, LLC 2111 Wilson Blvd., Suite 250 Arlington, VA 22201 Web: www.gene2drug.com • Phone: 703.778.3080 x13 • Fax: 703.778.3081 • Email: [email protected] Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Executive Summary Page 6 of 6
Order Form
o Purchase Order #_________________________________________
Name
Print: $3,200 $2,700 Electronic (.pdf): $5,200 $4,500 Enterprise: $7,940 $6,750
Capitalizing on New Opportunities for Stem Cell Products
Overview
REPORT #09-002
Report Objectives • Identify new/expanding stem cell research opportunities as a result of the ban on federal funding for research on human embryonic stem cells being lifted • Estimate market share for stem cell research products • Project growth of stem cell research products by market segment and geographic region • Learn types and species of stem cells scientists intend to use • Determine level of satisfaction with stem cell media and unmet needs with respect to stem cell products and cell lines • Uncover interest in integrated stem cell workflow products and services
This analysis also provides suppliers with critical insight into optimizing product offerings based upon scientists’ level of satisfaction with stem cell culture products and the level of interest in developing integrated stem cell product lines and services. The scientists surveyed share their opinions on what new product/technologies would be most beneficial to their research. Additionally, the report reveals what channels stem cell scientists use to access information relevant to their research, which in turn can be used by suppliers to more effectively target their products and services. The March 2009 policy change could have major implications for life science suppliers as academic scientists consider conducting research on previously unavailable embryonic stem cell lines. While the excitement about embryonic stem cell research is on the rise, including in the pharmaceutical and biotech industry, suppliers need actionable information about scientists’ plans to pursue research using all types of cell lines in a global market. This report provides insights into the origins and sources of stem cells currently used in the lab (adult, embryonic, induced and pluripotent) and those likely to be used over the next several years—in addition to differentiated cell types and associated diseases under investigation—allowing suppliers to anticipate the types of stem cell culture products scientists will need to purchase. Moreover, this report includes a supplemental section about scientists who plan to conduct stem cell research in the near future to help companies better anticipate the stem cell product needs of new customers. Capitalizing on New Opportunities for Stem Cell Products provides a roadmap for stem cell product suppliers to help navigate a landscape that is poised for change—and growth. This analysis was designed to guide suppliers in redirecting resources to new areas and markets, and to help refine current offerings by making them more responsive to scientists who are already engaged in stem cell research.
hoose C y h W eport? This R age 4) (see p
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
BioInformatics market insights from gene to drug 2111 Wilson Blvd Suite 250 Arlington, VA 22201 www.gene2drug.com 703.778.3081 (fax) Executive Summary Page 1 of 6
Analyst Expertise
In Capitalizing on New Opportunities for Stem Cell Products, we surveyed close to 500 scientists from around the world about their current—and planned—areas of research, usage of stem cell products and preferred suppliers. This report will help you to determine areas poised for growth (i.e., media, sera, supplements and cell lines) in the stem cell research products market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure your leading position in this
expanding market. For tactical planning purposes, the report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers. Combined with data on scientists’ stem cell research budgets and expected changes in spending through 2011, suppliers can use this information to anticipate areas of growth and product saturation.
Company Information
As a result of the March 9, 2009 reversal of the 2001 restrictions on federal funding of human embryonic stem cell research, suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell products market. Additionally, given that practical stem cellbased therapies can take years to develop, suppliers would benefit from a clear understanding of the wide range of products that support basic stem cell research already in progress. Capitalizing on New Opportunities for Stem Cell Products, BioInformatics LLC’s latest report, will enable suppliers to respond quickly to a market disrupted by an Executive Order, and to gain a better understanding of how today’s stem cell products market is driven by long-term stem cell research requirements.
Order Form
Overview
Report Highlights
This pre-publication discount price is only available until May 17, 2009!
Capitalizing on New Opportunities for Stem Cell Products REPORT #09-002
• Projected growth of stem cell research products market by market segment and geographic region • Anticipated stem cell research budgets for 2009 by market segment and geographic region • Expected change in spending on stem cell products and cell lines over the next two to three years (through 2011)
• Differentiated cell types that were/are/will be the focus of stem cell research for 2008, 2009, and two to three years from now (2010 and 2011) • Diseases that are the focus of stem cell research by type of stem cell • Top scientific journals respondents rate as most critical to their stem cell research • Critical stem cell conferences Stem Cell Culture Products: Top Suppliers and Budgets
• Suppliers from whom respondents purchase stem cell culture products
Frequently Asked Questions (related to):
• Products needed to support scientists’ current stem cell research
• Percent of stem cell culture product purchases made from leading suppliers
• Cell types and disease that are/will be the focus of stem cell research
• Estimated 2008 budget for stem cell culture products
• Use of embryonic versus induced pluripotent cells for specific applications • Unmet product needs and product differentiation strategies • New product and/or service development opportunities • Best channels by which to communicate with and market to stem cell researchers
Section 2. Methodology & Demographics
• Percent of 2008 budget spent on stem cell media, sera, and supplements • Estimated 2009 budget that will be dedicated to stem cell culture products and stem cell lines • Percent of 2009 budget that will be spent on stem cell media, sera, and supplements • Expected change in expenditures on stem cell media, sera, and supplements over the next two to three years (2010 and 2011) Stem Cell Media: Usage, Product Features and Special Requirements
• Objectives
• Types of media used to grow and culture stem cells
• Questionnaire design
• Percent of media that is custom vs. off-the-shelf
• Survey population
• Estimate of stem cell culture media used per month in 2008
Section 3. Presentation of the Survey Data: Respondents Conducting Stem Cell Research Research Overview and Applications
• Estimate of stem cell culture media expected to be used per month in 2009 • Expected change in stem cell culture media usage for two to three years from now (2010 and 2011) • Importance of xeno-free and animal-free types of stem cell culture media
• Length of time conducting research • Goals of stem cell research
Report Highlights
• Estimated market share of top suppliers by stem cell research product category (i.e., media, sera, supplements, and cells)
• Impact on research of lifting US restrictions on federal funding of embryonic stem cells
Analyst Expertise
• Estimated market share for stem cell research products by market segment and geographic region
• Features of stem cells studied
• Advantages of stem cell culture media from primary supplier
• Source, type, and number of different stem cell lines used in 2008
• Satisfaction with features of stem cell culture media from primary supplier
• Source, type, and number of different stem cell lines expected to be used in 2009
• Requirements for GMP conditions for stem cell culture products
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Executive Summary Page 2 of 6
Company Information
Market Size and Share and Market Growth Potential
• Source and type of stem cell lines plan to use two to three years from now (2010 and 2011)
Order Form
Section 1. Analysis
Overview
Report Highlights
Capitalizing on New Opportunities for Stem Cell Products REPORT #09-002 Additional Analysis by:
• General sources from which respondents acquire stem cells
• Market segment
• Percent of stem cell purchases made from major sources in 2008
• Years of experience
• Percent of stem cell purchases expected to be made from major sources in 2009
• Research focus
• Geographic region
age (see p
4
• Lab size
• Commercial suppliers and/or national bank/repositories from which respondents currently purchase stem cells
Section 4. Appendices
• Percent of stem cell purchases made from commercial suppliers and/or national bank/repositories
Appendix A. Respondents Planning to Conduct Stem Cell Research
• Estimated 2008 budget for stem cell lines • Estimated 2009 budget that will be dedicated to stem cell lines • Reasons why respondents acquire stem cells from their primary suppliers • Percent of stem cells grown on feeders and sources of feeder cells • Use of 3-D cell culture in stem cell research • Reasons for interest in 3-D cell culture for stem cell research Supporting Products, Technologies, and Services
• Techniques respondents use to identify differentiated cell types derived from stem cells • Major disadvantages of techniques used to identify differentiated cell types derived from stem cells • Primary supplier of consumable products used to perform techniques for identifying differentiated cell types derived from stem cells • Stem cell-specific kits or panels currently used and planned to use in the next 12 months • Stages of stem cell workflow processes with which respondents are involved
• Time frame that respondents plan to begin stem cell research • Sources of funding that will support future stem cell research • Anticipated annual budget for stem cell culture products and stem cell lines • Sources and types of stem cells respondents plan to use in their research
Analyst Expertise
Report Highlights
• Stem cell type
• Differentiated cell types that will be the focus of stem cell research • Diseases that will be the focus of stem cell research by cell type • Sources from which respondents plan to acquire stem cells Appendix B. Verbatim Responses to Questions
Company Information
• Expected changes in the percent of stem cell purchases expected to be made from commercial suppliers over the next two to three years (2010 and 2011)
hoose Why C port? e This R )
• Do you think your stem cell research will change due to the lifting of US restrictions on federal funding for human embryonic stem cell research by the new presidential administration? Why or why not? • Like many stem cell pioneers, Ian Wilmut, the creator of Dolly the sheep, has embraced an alternative approach. Are induced pluripotent stem cells the beginning of the end for embryonic cloning? Why or why not?
• Stage of stem cell workflow that respondents would most like a new product/technology to facilitate their research • Types of stem cell-related services that respondents would be most interested in obtaining from suppliers .
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Executive Summary Page 3 of 6
Order Form
Stem Cells: Sources, Budgets, and Special Requirements
Overview
Report Highlights (continued)
#09-001
Prospering in a Down Market: Strategies for Life Science Suppliers
March 2009
159 Pages
#08-047
The Brave New World of Scientific Publishing
November 2008
154 Pages
#08-019
Enabling Discovery: The 2008 Life Science Industry Awards
June 2008
101 Pages
#08-008
Instrumentation Service Contracts: Opportunities for Differentiation
July 2008
136 Pages
#08-007
Protein Research: Strategies for Marketing to Chemists and Biologists
September 2008
123 Pages
#08-006
Understanding Switching Dynamics: Maximizing Customer Retention in the Life Science
March 2008
173 Pages
#08-004
Life Science Product Catalogs: Techniques to Increase Sales
March 2008
92 Pages
#08-003
Conference & Exhibit Strategies in the Life Sciences: What’s Working Now
February 2008
135 Pages
#08-002
Advertising to Life Scientists: Resolving the Print vs. Online Dilemma
February 2008
105 Pages
#08-001
Marketing to Life Scientists: Capturing Customers’ Attention in Applied Markets
January 2008
156 Pages
TM
Report Highlights
Life Science Marketing
Overview
Other Recent Publications*
Sources of Independent, Unbiased Research Unlike reports from other firms that are based on an analyst’s subjective summary of information from publicly available sources, our reports are based on the results of detailed surveys of hundreds—even thousands—of scientific and medical professionals who buy your products.
Carefully Selected Survey Participants When others promote results from their online surveys, they fail to mention the uncontrolled nature of their broadcast email invitations. To provide you with the most valid and accurate results possible, the respondents to our surveys are members of our unique online panel—The Science Advisory Board—which consists of more than 43,000 verified life science and biomedical professionals who have agreed to take part in our surveys, focus groups and other market research activities. These respondents are carefully selected based on their professional qualifications, market segments and geographic regions—we can even select them based on the products they use and their preferred suppliers.
Don’t settle for an imitation. Invest in the most direct source of information from the scientists who buy your products, and the expert team that has been monitoring your clients since 1994.
Developed by a Team of Experts Complimentary Consulting Provided
Our questionnaires are developed by a multidisciplinary team of scientists, industry veterans and market research experts with years of experience. These professionals understand that survey questions need to be asked in a way that ensures the answers will directly address the business challenges you face. Once the survey data is collected, this same team creates a unique report that presents the reader with a thorough understanding of the topic and the scientific and business implications of the results based on sophisticated statistical analytics.
With your purchase, we offer one free hour of consultation with our talented team of scientific and business analysts who created the report. During this consultation, we can answer any questions you may have about the survey results and what we believe to be the significant trends affecting the market.
Custom Analysis & Research Available If you’d like to delve deeper into the data from a study, we can always perform custom cross-tabulations or other analysis on your behalf. We can even pose follow-up questions to respondents who answered in a particular way or conduct a custom study to extend your knowledge.
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Executive Summary Page 4 of 6
Company Information
The design and analysis of Capitalizing on New Opportunities for Stem Cell Products was spearheaded by BioInformatics LLC’s Vice President of Advisory Services Tamara Zemlo, Ph.D., MPH, who has been the lead analyst on over 80 syndicated market research reports. For this study, Dr. Zemlo consulted with multiple stem cell products vendors to optimize the relevance of this study with regards to the current stem cell research market.
Order Form
With hundreds of stem cell products market reports to choose from, why choose ours?
Analyst Expertise
* See Web site www.gene2drug.com for a complete listing.
Our Valued Clients Biotechnology/Life Science 454 AbCam Accelrys Affymetrix Agencourt Bioscience Agilent Technologies American Type Culture Collection Anachem Antibodies By Design Apple Computer Applied Biosystems Applied Precision Axxora BD Biosciences Beckman Coulter Biacore Bio-Rad Laboratories Bioneer Biotage BioTrove Blue Heron Biotechnology Caliper Technologies Callida Genomics Cambrex Bio Science Carl Zeiss Cell Signaling Technology Celliance Charles River Laboratories ChromaVision Medical Systems Cipher Systems Clontech Laboratories Corning DAKO DNAStar Dow Corning Dynal Biotech eBIOINFORMATICS Edge Biosystems Eksigent Technologies EM Separations Technology EMD Biosciences Entelechon Epigenomics Epitomics Epoch Biosciences
Eppendorf Eurogentec Expression Pathology Fermentas Fluidigm GE Healthcare Gen-Probe Gene Codes Gene Logic Gene Therapy Systems Gentra Systems GenVault Corporation Genzyme Guava Technologies Helicos BioSciences Hewlett-Packard High Throughput Genomics Hitachi Instruments Hybrigenics Hyseq IBM Life Sciences Illumina Immunotech InforMax Integrated DNA Technologies Invitrogen JRH Biosciences Kirkegaard & Perry Laboratories Kodak Scientific Imaging Leica Microsystems LI-COR LION bioscience Lonza Luminex MDS Sciex Mettler-Toledo AutoChem Millipore MiraiBio Molecular Devices MWG Biotech New England Biolabs NuGEN Technologies Ovid Technologies Pall Life Sciences Percival Scientific PerkinElmer Life Sciences Photometrics
Plexagen Diagnostics Post Genome Institute Promega Protein Forest Proteome Systems Qbiogene QIAGEN R & D Systems Ribomed Biotechnologies Rosetta Biosoftware Sachem Sarstedt Sandia National Laboratories SAS Institute Schott Nexterion Sequenom Serologicals Serotec Sigma-Aldrich Solexa SomaLogic Source Precision Medicine Stratagene Stressgen Biotechnologies Takara Mirus Bio Tecan The Jackson Laboratory Thermo Fisher Scientific Thomas Scientific Tocris Cookson Transgenomic UVP Varian VWR International Vysis Waters Whatman Medical Diagnostics Applied Imaging Ciba Corning Diagnostics Dade Behring Diagnostic Products Diametrics Medical Hewlett-Packard Medical Products LifeScan Mallinckrodt
Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Ortho-Clinical Diagnostics Radiometer America Tektronix Pharmaceuticals Abbott Laboratories Amgen AstraZeneca Aventis Baxter Healthcare Bayer Boehringer Ingelheim Pharmaceuticals Cardinal Health Centocor Hoechst Marion Roussel ICN Pharmaceuticals Janssen Pharmaceutica Merck Novartis Pharmaceuticals Novo Nordisk Pharmaceuticals Pfizer Schering-Plough Professional Services & Finance Adjuvant Partners Adventus Research Agency.com Anvil Group Atlas Venture Battelle Memorial Institute BioOnline Citadel Investment Group Doran Media Services Fidelity Management and Research Foley & Lardner Gerson Lehrman Group HSBC Securities Infotrieve Innovative Marketing Group McKinsey & Co. Nathan Associates National Research Council of Canada Novintel
Phillip Johnson & Associates PA Consulting Perry Ballard Piper Jaffray Ruder Finn Scherago International Select Equity Group Stephan & Brady The Strategy Works UBS Warburg Publishers & Associations Academic Press American Academy of Pediatrics AAAS/Science American Medical Association American Society for Cell Biology American Society for Microbiology American Society of Human Genetics BioTechniques/Eaton Publishing Blackwell Publishing Cold Spring Harbor Laboratory Press Elsevier Federation of Amer. Societies for Experimental Biology Harvard University Medical School John Wiley & Sons Mary Ann Liebert Publishers Nature Publishing Group New England Journal of Medicine Society for Neuroscience Springer-Verlag Stanford University High Wire Press Thomson ISI Wolters Kluwer
Executive Summary Page 5 of 6
Overview Report Highlights
BioInformatics offers both published reports and custom research services. Published reports allow marketing professionals to share in the results of broad-based market studies that provide access to high quality research at an affordable price. Our custom research is tailored to the specific needs of the company’s executive management. For more information about BioInformatics’ product and service offerings, please visit our Web site at www.gene2drug.com, call 703.778.3080 or email [email protected].
Analyst Expertise
Our multi-disciplinary team of scientific experts and business analysts creates value for our clients by combining extensive industry knowledge and experience. We offer a variety of products and services that enable executives to see themselves, their market and their competitors through the eyes of the most important information source of all—customers. We can precisely meet the needs of our clients through the most appropriate mix of research methodologies, including: • Online Surveys • Online Focus Groups • Mail Surveys • Telephone Interviews
Company Information
Since our inception in 1994, BioInformatics has provided critical market intelligence to leading companies serving the life science, medical device and pharmaceutical industries. We support clients across the entire market spectrum—from scientific research to diagnostics and therapeutics—providing high-level management with market insights from gene to drug.
Our strength lies in our ability to integrate our understanding of science and medicine with cutting-edge market research techniques. As one of the first firms to recognize how the World Wide Web has transformed market research, BioInformatics formed The Science Advisory Board. Launched in 1997, this global community currently consists of more than 43,000 life science researchers, physicians and biomedical professionals who convene regularly via the Web to voice their opinions on a wide variety of issues relating to biomedical research and clinical technologies. Clients tap into this panel of experts and receive answers to their critical marketing questions in days, rather than weeks. In addition to providing real-time insights into the perceptions of the market, posing questions to The Science Advisory Board offers substantial cost savings over gathering information via traditional market research techniques.
Order Form
About BioInformatics, LLC
BioInformatics market insights from gene to drug
REPORT #09-002
Overview
Capitalizing on New Opportunities for Stem Cell Products PRE-PUBLICATION DISCOUNT PRICES are only available until May 17, 2009! Print Copy—$3,200 Now $2,700! Electronic Copy (includes one print copy)—$5,200 Now $4,500! Enterprise Copy (includes one print copy)—$7,940 Now $6,750!
Ordering Information
Payment must be made within 30 days and in U.S. dollars. BioInformatics’ Federal Tax ID #: 54-2001907.
This format allows an unlimited number of users within your company to access the report regardless of geographic location. You may place the electronic copy (PDF) on your secure, corporate intranet or share it with co-workers via email. In addition to providing greater accessibility, the electronic copy allows you to easily navigate the document with the help of bookmarks, quickly search key words or phrases and print out any page. One print copy of the report is also provided at no additional cost.
Credit Card
Data Set
You may charge your order to American Express, MasterCard, Visa, Diner’s Card or Discover. Please include your credit card account number, expiration date and signature.
To accommodate your unique needs, the raw data is also available. With the data, you can analyze respondents’ answer choices in any way needed, including cross-tabulations, correlations, etc. The data set is offered in two formats: SPSS® Base or Microsoft® Excel, and may only be purchased in conjunction with the company-wide electronic copy of the report.
Analyst Expertise
Wire transfers should be sent to: SunTrust Bank, 2121 15th Street, Arlington, VA 22201, SWIFT #SNTRUS3A, ABA #071000104, Account #702260169.
I wish to order the following format of REPORT #09-002, Capitalizing on New Opportunities for Stem Cell Products
Discount Price
$2,700
$________
$4,500
$________
$6,750
$________
Excel or SPSS (circle one)
+$1,200
+$________
o Print Copy o Electronic Copy (.pdf, includes print copy)
o Enterprise Copy (.pdf, includes print copy) o Add Data Set
Additional print copies
_____ x $300 each
+$________
Promo Code ___________ –$________ Shipping & Handling (Add $15 for U.S., $50 for Int’l) +$________ Total $________
Company Information
Wire Transfers
Report Highlights
Electronic Copy
To place an order, fill out this form and mail it to BioInformatics, LLC or fax it to 703.778.3081. Alternatively, you may submit your order by emailing [email protected], calling 703.778.3080 or visiting www.gene2drug.com/order/201/.
o Check Enclosed (Payable to BioInformatics, LLC)
o Bill Me Title
o Am Ex o MasterCard o Visa o Diner’s Card o Discover
Organization
/
Street Address
Credit Card #
City, State/Province, Postal Code
Exp Date (MM/YY)
Name on card______________________________________________
Country
Order Authorized By: Phone
Fax
__________________________________________________________ Signature
Date
BioInformatics, LLC 2111 Wilson Blvd., Suite 250 Arlington, VA 22201 Web: www.gene2drug.com • Phone: 703.778.3080 x13 • Fax: 703.778.3081 • Email: [email protected] Capitalizing on New Opportunities for Stem Cell Products ©2009 BioInformatics, LLC
Executive Summary Page 6 of 6
Order Form
o Purchase Order #_________________________________________
Name
Related Documents
09-002 Stemcells Execsumm
April 2020 0
Peri Report Execsumm
May 2020 0
Ots 24 > 24071 > Execsumm
November 2019 8
